An update on: Meta-analysis of medical and non-medicaltreatments of the prodromal phase of Psychotic Illness in at risk Mental States

Psychiatria Danubina

Volumn 28, Issue , 2016, Pages 31-38

  Deas, Gavin ^a   Kelly, Christopher ^g,h   Hadjinicolaou, Andreas V ^e,f   Holt, Clare ^d   Agius, Mark ^b,c   Zaman, Rashid ^b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MERTON COLLEGE   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anti depressants; Anti psychotics; At risk mental state; Cognitive behaviour therapy; Omega 3 poly unsaturated fatty acids

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; RISPERIDONE;

ADVERSE OUTCOME; COGNITIVE BEHAVIORAL THERAPY; COGNITIVE THERAPY; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILY AIDED ASSERTIVE COMMUNITY TREATMENT; GROUP THERAPY; HIGH RISK PATIENT; HUMAN; MENTAL HEALTH; META ANALYSIS; PHASE TRANSITION; PRODROMAL SYMPTOM; PSYCHIATRIC TREATMENT; PSYCHOSIS; RISK; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION;

EID: 84989875819     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Addington JI, Epstein I, Liu L., French P, Boydell KM, Zipursky RB: A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 2011; 125:54-61.
2. Agius M, Bradley V, Ryan D., Zaman R: The ethics ofidentifying and treating psychosis early. Psychiaria Danubina 2008; 20:93-96.
3. Amminger P, Schäfer M, Papageorgiou K., Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry P.D., Berger GE: Long-Chain-3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled Trial. Arch Gen Psychiatry 2010; 67:146-154.
4. Amminger GP, Schäfer MR, Schlögelhofer M, Klier C.M., McGorry PD: Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun 2015; 11:7934.
5. Bechdolf A, et al: Randomized controlled multicenter trial of cognitive behaviour therapy in the early initial-prodromal state: effects on social adjustment posttreat-ment. Early Intervention in Psychiatry 2007; 1:71-78.
6. Bechdolf A, Wagner M, Ruhrmann S., Harrigan S, Putzfeld V, Pukrop R., Brockhaus-Dumke A, Berning J, Janssen B, Decker P, Bottlender R, Maurer K, Möller HJ, Gaebel W, Häfner H, Maier W, Klosterkötter J: Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 2012; 200:22-9.
7. Bentall RP, Morrison AP: More harm than good; The case against using antipsychotic drugs to prevent severe mentalillness. J Mental Health 2002; 11:351-356.
8. Berger G, Dell'Olio M, Amminger P, Cornblatt B, Phillips L, Yung A, Yan Y, Berk M, McGorry P: Neuroprotectionin emerging psychotic disorders, Early Intervention in Psychiatry 2007; 1:114-127.
9. Berger GE, Wood SJ, Ross M, Hamer C.A., Wellard RM, Pell G, Phillips L, Nelson B., Amminger GP, Yung AR, Jackson G, Velakoulis D, Pantelis C, Manji H, McGorry PD: Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr Pharm Des 2012; 18:570-5.
10. Bošnjak D., Kekin I, Hew J., Rojnic Kuzman M: Early interventions for prodromal stage of psychosis. Cochrane Schizophrenia Group, 2016.
11. Cannon TD, Cadenhead K, Cornblatt B., Woods SW, Addington J, et al: Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65:28-3.
12. Cornblatt BA, Lencz T, Smith C.W., Correll CU, Auther AM, Nakayama E: The Schizophrenia Prodrome Revisited: A Neurodevelopmental Perspective. Schizophrenia Bulletin 2003; 29:633-651.
13. Cornblatt BA, Lencz T, Smith C.W., Olsen R., Auther AM, Nakayama E, et al: Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007; 68:546-57.
14. Duffy FH, D'Angelo E, Rotenberg A, Gonzalez-Heydrich J: Neurophysiological differences between patients clinically at high risk for schizophrenia and neurotypical controls - first steps in development of a biomarker. BMC Med 2015; 13:276.
15. Ising HK, Smit F, Veling W., Rietdijk J, Dragt S, Klaassen R.M., Savelsberg NS, Boonstra N, Nieman DH, Linszen DH, Wunderink L, van der Gaag M: Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial. Psychol Med 2015; 45:1435-46.
16. McFarlane WR, Levin B, Travis L., Lucas FL, Lynch S, Verdi M, Williams D., et al: Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. Schizophr Bull 2015; 41:30-43.
17. Marshall M & Rathbone J: Early intervention for psychosis. Cochrane Schizophrenia Group, 2011.
18. McGorry, PD, Yung AR: Randomized Controlled Trial of Interventions Designed to Reduce the Risk of Progression to First-Episode Psychosis in a Clinical Sample With Subthreshold Symptoms. Arch Gen Psychiatry 2002; 59:921-928.
19. McGorry PD, Nelson B, Phillips L.J., Yuen HP, Francey SM, Thampi A, Berger G.E., Amminger GP, Simmons MB, Kelly D, Dip G, Thompson AD, Yung AR: Randomized controlled trial of interventions for young people at ultrahigh risk of psychosis: twelve-month outcome. J Clin Psychiatry 2013; 74:349-56.
20. Morrison AP, Bentall RP, Walford F.L., Kilcommons A., Knight A, Kreutz M, Lewis SW: Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry 2002; 181(suppl. 43);s78-s84.
21. Morrison AP, French P, Walford L et al: A randomized controlled trial of cognitive therapy for prevention of psychosis in people at ultra-high risk. Schizophrenia Research 2004; 67:7.
22. Morrison AP, French P, Stewart S.L., Birchwood M., Fowler D, Gumley AI, Jones P.B., Bentall RP, Lewis SW, et al: Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 2012; 344:e2233.
23. Nordentoft M, Thorup A, Petersen L., Øhlenschlaeger J, Melau M, Christensen T, Krapup G, Jorgensen P, Jeppesen P: Transition rates from schizotypal disorder topsychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophrenia Research 2006; 83:29-40.
24. McGlashan TH, Zipursky RB, Perkins D, Addington J., Miller T, Woods SW, Hawkins K.A., Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A: Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. Am J Psychiatry 2006; 163:790-799.
25. Ruhrmann S, Bechdolf A, Kühn KU, Wagner M., Schultze-Lutter F, Janssen B, Maurer K., Häfner H, Gaebel W, Möller HJ, Maier W, Klosterkötter J, LIPS study group: Acute effects of treatment for prodromal symptoms forpeople putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry 2007; 191(suppl. 51):s88-95.
26. Van der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RM, Koeter M, Cuijpers P, Wunderink L, Linszen DH: Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 2012; 38:1180-8.
27. Woods SW, Tully EM, Walsh B.C., Hawkins KA, Callahan JL, Cohen SJ, Mathalon D.H., Miller TJ, McGlashan TH: Aripiprazole in the treatment of the psychosis prodrome. An open-label pilot study. British Journal of Psychiatry 2007; 191(suppl. 51):s96-s101.
28. Woods S1, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH: Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuro-psychopharmacol 2013; 23:931-40.
29. Woolson RF: Statistical Methods for the Analysis of Biomedical Data Page 251, New York NY: John Wiley and Sons Inc, 1987.
30. Yung AR, McGorry PD: The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z. J Psychiatry 1996; 30:587-99.
31. Yung AR, Phillips LJ, Yuen H.P., Francey SM, McFarlane CA, Hallgren M, McGorry PD: Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group Schizophr Res 2003; 60:21-32.
32. Yung AR, Phillips LJ, Nelson B, Francey S.M., Pan Yuen H, Simmons MB, Ross M.L., Kelly D., Baker K, Amminger GP, Berger G, Thompson AD, Thampi A, McGorry PD: Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. Clin Psychiatry 2011; 72:430-40.